Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases.
COVID-19
Re-infections
Rheumatic diseases
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
29 Mar 2024
29 Mar 2024
Historique:
received:
09
01
2024
accepted:
27
02
2024
medline:
29
3
2024
pubmed:
29
3
2024
entrez:
29
3
2024
Statut:
aheadofprint
Résumé
Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls. Logistic regression analysis was performed to assess potential milder re-infection versus primary infection severity, adjusting for study group, demographics (age, sex), vaccination status, body mass index, smoking, and comorbidities. 23 and 7 out of 167 re-infected SRD patients experienced two and three re-infections, respectively, which were comparable to the re-infection rates in controls (two: 32; and three: 2) who also had comparable COVID-19 vaccination history (89% and 95% vaccinated, respectively). In the initial infection, patients with SRDs were hospitalized (7.2% versus 1.8%, p = 0.017), and had received antiviral treatment (16.1% versus 4.7%, p < 0.001) more frequently than controls. However, hospitalizations (1.8% vs 0.6%) and antiviral treatment (7.8% vs 3.5%) did not differ (p > 0.05) between patients and controls at the first re-infection, as well as during the second and third re-infection; no deaths were recorded. Perceived severity of re-infections was also comparable between patients and controls (p = 0.847) and among those on biologic DMARDs or not (p = 0.482). In multivariable analysis, neither SRDs presence nor demographics or comorbidities were associated with COVID-19 re-infection severity. COVID-19 re-infection severity (patient-perceived/hospitalizations/deaths) did not differ between SRDs and controls.
Identifiants
pubmed: 38548908
doi: 10.1007/s00296-024-05573-w
pii: 10.1007/s00296-024-05573-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Conway R, Grimshaw AA, Konig MF et al (2022) SARS–CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol 74:766–775
doi: 10.1002/art.42030
pubmed: 34807517
pmcid: 9011807
Wang Q, Liu J, Shao R, Han X, Su C, Lu W (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41:851–861
doi: 10.1007/s00296-021-04803-9
pubmed: 33687528
pmcid: 7941871
Bournia V-K, Fragoulis GE, Mitrou P et al (2023) Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology 62:1047–1056
doi: 10.1093/rheumatology/keac422
pubmed: 35920774
Lawson-Tovey S, Hyrich KL, Gossec L et al (2022) SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 81:145–150
doi: 10.1136/annrheumdis-2021-221217
pubmed: 34489305
Papagoras C, Fragoulis GE, Zioga N et al (2022) Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis 81:1013–1016
doi: 10.1136/annrheumdis-2021-221539
pubmed: 34758975
Papagoras C, Zioga N, Papadopoulos V et al (2023) Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol 42:3375–3385
doi: 10.1007/s10067-023-06769-4
pubmed: 37731083
pmcid: 10640401
Horita N, Fukumoto T (2023) Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic. J Med Virol 95:e28231
doi: 10.1002/jmv.28231
pubmed: 36253938
Cook C, Patel NJ, D’Silva KM et al (2022) Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann Rheum Dis 81:289–291
doi: 10.1136/annrheumdis-2021-221326
pubmed: 34489304
Fragoulis GE, Karamanakos A, Arida A et al (2022) Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD Open 8:e002279
doi: 10.1136/rmdopen-2022-002279
pubmed: 35246472
Bournia V-K, Fragoulis GE, Mitrou P, Mathioudakis K, Konstantonis G, Tektonidou MG, Tsolakidis A, Paraskevis D, Sfikakis PP (2023) Outcomes of COVID-19 omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study. Rheumatology. https://doi.org/10.1093/rheumatology/kead354
doi: 10.1093/rheumatology/kead354
pubmed: 37467059
Fragoulis GE, Koutsianas C, Fragiadaki K et al (2022) Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series. Ann Rheum Dis 81:1477–1479
doi: 10.1136/annrheumdis-2022-222845
Bobrovitz N, Ware H, Ma X et al (2023) Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 23:556–567
doi: 10.1016/S1473-3099(22)00801-5
pubmed: 36681084
pmcid: 10014083
Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA (2022) SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res 209:112911
doi: 10.1016/j.envres.2022.112911
pubmed: 35149106
pmcid: 8824301
Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J (2023) Severity and outcomes of SARS-CoV-2 reinfection compared with primary infection: a systematic review and meta-analysis. Int J Environ Res Public Health 20:3335
doi: 10.3390/ijerph20043335
pubmed: 36834029
pmcid: 9961977
Krasselt M, Wagner U, Nguyen P, Pietsch C, Boldt A, Baerwald C, Pierer M, Seifert O (2022) Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology 61:SI180–SI188
doi: 10.1093/rheumatology/keac089
pubmed: 35143648
Wieske L, van Dam KPJ, Steenhuis M et al (2022) Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol 4:e338–e350
doi: 10.1016/S2665-9913(22)00034-0
pubmed: 35317410
pmcid: 8930018
Feikin DR, Higdon MM, Abu-Raddad LJ et al (2022) Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399:924–944
doi: 10.1016/S0140-6736(22)00152-0
pubmed: 35202601
pmcid: 8863502
Fragoulis GE, Evangelatos G, Arida A et al (2021) Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis 80:e60–e60
doi: 10.1136/annrheumdis-2020-217935
pubmed: 32475830
Fragoulis GE, Evangelatos G, Arida A et al (2020) Nocebo-prone behaviour in patients with autoimmune rheumatic diseases during the COVID-19 pandemic. Mediterr J Rheumatol 31:288
doi: 10.31138/mjr.31.3.288
pubmed: 33196007
pmcid: 7656135
Chan EKH, Williams V, Romano C et al (2023) Psychometric evaluation of the symptoms of infection with coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial. J Patient Rep Outcomes 7:1–12
doi: 10.1186/s41687-023-00581-z
Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment—digital collections—national library of medicine. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-9918232103906676-pdf . Accessed 27 Jan 2024
Rofail D, Griffiths P, Flore G, Hussein M, Sivapalasingam S, Podolanczuk AJ, Rodriguez AM, Mastey V, Gwaltney C (2022) Reliability and validity of an instrument of COVID-19 patient-reported symptoms in outpatients. JAMA Netw Open 5:e2239053
doi: 10.1001/jamanetworkopen.2022.39053
pubmed: 36306132
pmcid: 9617168
Rofail D, McGale N, Im J, Rams A, Przydzial K, Mastey V, Sivapalasingam S, Podolanczuk AJ (2022) Development and content validation of the symptoms evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies. J Patient Rep Outcomes 6:41
doi: 10.1186/s41687-022-00448-9
pubmed: 35507193
pmcid: 9066128